Ventyx Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
Ventyx Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
Ventyx Biosciences (VTYX) Receives a Buy From LifeSci Capital
Stifel Nicolaus Keeps Their Hold Rating on Ventyx Biosciences (VTYX)
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)
Ventyx Biosciences (VTYX) Receives a Buy From Oppenheimer
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)
Ventyx Biosciences: A Prudent Hold Amidst Promising Drug Potential and Market Uncertainties
Buy Rating for Ventyx Biosciences Based on Clinical and Financial Strengths
Ventyx Biosciences (VTYX) Gets a Buy From LifeSci Capital
Ventyx Biosciences Analyst Ratings
Buy Rating Affirmed for Ventyx Biosciences on Strong Clinical Pipeline and Promising Drug Developments
Buy Rating Affirmed: Ventyx Biosciences' Promising Clinical Advances and Strategic Position for Market Opportunities
Hold Rating on Ventyx Biosciences Amid Pipeline Uncertainties and Strategic Partnerships Search
Canaccord Genuity Maintains Buy on Ventyx Biosciences, Lowers Price Target to $16
Maintaining Hold on Ventyx Biosciences Amidst Anticipation of NLRP3 Inhibitor Data and Financial Stability
Lifesci Capital Upgrades Ventyx Biosciences to Outperform From Market Perform, $5 Price Target
Ventyx Biosciences (VTYX) Receives a Buy From Piper Sandler